MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
49.82
+0.49 (0.99%)
Nov 20, 2024, 4:00 PM EST - Market closed
MLTX Employees
MoonLake Immunotherapeutics had 50 employees as of December 31, 2023. The number of employees increased by 30 or 150.00% compared to the previous year.
Employees
50
Change (1Y)
30
Growth (1Y)
150.00%
Revenue / Employee
n/a
Profits / Employee
-$1,615,362
Market Cap
3.14B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BrightSpring Health Services | 35,000 |
| Acadia Healthcare Company | 23,500 |
| Bausch Health Companies | 20,270 |
| Neogen | 2,917 |
| Inari Medical | 1,300 |
| PTC Therapeutics | 1,055 |
| Veracyte | 815 |
| Denali Therapeutics | 445 |
MLTX News
- 2 months ago - MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 - GlobeNewsWire
- 4 months ago - MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward - Seeking Alpha
- 6 months ago - MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa - GlobeNewsWire
- 6 months ago - MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion - Seeking Alpha
- 7 months ago - MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 8 months ago - MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions - GlobeNewsWire
- 8 months ago - MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions - Business Wire
- 9 months ago - MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day - GlobeNewsWire